By Dr John Maher (Leucid Bio)2023-07-03T11:21:10
Dr John Maher discusses the challenges associated with developing chimeric antigen receptor (CAR) T-cell therapy for solid tumours.
Dr John Maher, founder and Chief Scientific Officer of Leucid Bio, responds to questions about how to overcome the challenges associated with developing chimeric antigen receptor (CAR) T-cell therapy for solid tumours and how the clinical stage biotech company is making strides towards this goal.
2026-11-20T13:00:00Z
2026-11-20T08:00:00Z
Contributor Dr Rahul Gupta, By Drug Target Review
2026-11-18T11:12:00Z
2026-11-18T07:00:00Z
Contributor Dr Bryan McClellan and Dr William Matsui, By Drug Target Review
2026-11-18T07:00:00
Contributor Dr Bryan McClellan and Dr William Matsui, By Drug Target Review
2025-10-08T14:00:00
Sponsored by Eurofins Discovery
2023-05-30T13:51:56
Sponsored by BPS Bioscience
2023-01-06T10:25:33
Sponsored by Leica Microsystems
2025-11-19T16:00:00
Sponsored by Eurofins DiscoverX
Site powered by Webvision Cloud